% | $
Quotes you view appear here for quick access.

Ironwood Pharmaceuticals, Inc. Message Board

  • jrus2010 jrus2010 Jan 31, 2013 7:05 AM Flag

    Quality of the data will ensure Linzess predominance

    As details of Synergy's clinical trials emerge, I expect investors to realize important differences in trial design and quality of the data that will make it clear that Ironwood's drug will be the only agent of its class on the market for the foreseeable future. Channel checks indicate rapid uptake and increasing traction for Linzess in January which will translate to better than expected revenue growth.

    Sentiment: Strong Buy

13.91+0.16(+1.16%)Oct 20 4:00 PMEDT